心不全における心房細動の管理:誰,いつ,どのように?
Panteleimon E Papakonstantinou1, Gregory Y H Lip2,3,4
1Atrial Fibrillation Institute, Heart and Vascular Centre and Cardiovascular Research Institute Dublin, Royal College of Surgeons of Ireland, Mater Private Hospital, Dublin, Ireland.
International journal of heart failure
|February 16, 2026
まとめ
心不全 (HF) 患者における心房細動 (AF) の管理は複雑である. 早期のリズムコントロール,特にカテーテル除去は,選択されたHF患者の生存率を改善し,入院数を減らすことを示しています.
科学分野:
- 心臓病学 心臓病学
- 電気生理学 電気生理学
- 心不全管理について
背景:
- 心房細動 (AF) と心不全 (HF) はしばしば共存し,お互いの進行と結果を悪化させます.
- HF患者のAFの管理には,リズム制御,速度制御,および抗凝固剤に関する複雑な決定が必要です.
研究 の 目的:
- HF患者におけるAFの管理に関する現在の証拠を統合する.
- HFにおける統合された,患者中心のAF管理のための実用的な臨床アルゴリズムを提供すること.
主な方法:
- 最近のランダム化試験と更新されたガイドラインのナラティブレビュー.
- AFとHFを結びつける病理生理学的メカニズムの分析.
- カテーテル除去を含むリズム制御戦略の評価.
主要な成果:
- 早期のリズム制御,特にカテーテルアブレーションは,生存率を向上させ,エジェクション分数が減少した選択されたHF患者でHF入院を減少させます.
- 共有された病理生理学的メカニズムには,神経ホルモンの活性化,構造的改造,心房筋病気が含まれる.
- 直接投与される経口抗凝固剤は,血栓栓塞栓のリスクを低減する上で重要な役割を果たします.
結論:
- カテーテルアブレーションは,エジェクション分数が減少したHFの好ましいリズム制御戦略です.
- AF介入の最適なタイミングと方法は,患者特有の要因に依存します.
- 統合された,多学科的,患者中心のケアは,HFにおけるAFの管理に不可欠です.
関連する概念動画
01:22Heart Failure VI: Adjunct Therapies
403
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
403
01:30Heart Failure V: Medical Management
369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369
01:25Dysrhythmias VI: Management of Dysrhythmias
498
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
498
01:22Heart Failure Drugs: β-Blockers
984
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
984
01:30Heart Failure IV: Classification and Diagnostic Evaluation
441
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
441
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K